Evidence map›Paper›PMID 29316899›Full record

ArticleBMC neurology2018

Plasma long non-coding RNA BACE1 as a novel biomarker for diagnosis of Alzheimer disease.

Liang Feng, Yu-Ting Liao, Jin-Cai He, Cheng-Long Xie, Si-Yan Chen, Hui-Hui Fan, Zhi-Peng Su, Zhen Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 4 pooled it
4.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 4 syntheses or guidelines pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Liang FengDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Yu-Ting LiaoInstitute of public health management of Wenzhou Medical University, Wenzhou, Wenzhou, 325000, China.
Jin-Cai HeDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Cheng-Long XieDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Si-Yan ChenDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Hui-Hui FanInstitute of public health management of Wenzhou Medical University, Wenzhou, Wenzhou, 325000, China.
Zhi-Peng SuDepartment of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China. drsuzhipeng@163.com.
Zhen WangDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China. jane.wz@163.com.
First Affiliated Hospital of Wenzhou Medical University · CNWenzhou Medical University · CN

Funding

NSFC No.81600977Projects of Wenzhou city Committee of Science and Technology 2014Y0171
6 · The paper itself

Abstract

backgroundsLong non-coding RNA (LncRNA) have been reported to be involved in the pathogenesis of neurodegenerative diseases, but whether it can serve as a biomarker for Alzheimer disease (AD) is not yet known.

methodsThe present study selected four specific LncRNA (17A, 51A, BACE1 and BC200) as possible AD biomarker. RT-qPCR was performed to validate the LncRNA. Receiver operating characteristic curve (ROC) and area under the ROC curve (AUC) were applied to study the potential of LncRNA as a biomarker in a population of 88 AD patients and 72 control individuals.

resultsWe found that the plasma LncRNA BACE1 level of AD patients was significantly higher than that of healthy controls (p = 0.006). Plasma level of LncRNA 17A, 51A and BC200 did not show a significant difference between two groups (p = 0.098, p = 0.204 and p = 0.232, respectively). ROC curve analysis showed that LncRNA BACE1 was the best candidate of these LncRNA (95% CI: 0.553-0.781, p = 0.003). In addition, no correlation was found for expression of these LncRNA in both control and AD groups with age or MMSE scale (p > 0.05).

conclusionsOur present study compared the plasma level of four LncRNA between AD and non-AD patients, and found that the level of the BACE1 is increased in the plasma of AD patients and have a high specificity (88%) for AD, indicating BACE1 may be a potential candidate biomarker to predict AD.

Indexed as

Alzheimer DiseaseAmyloid Precursor Protein SecretasesAspartic Acid EndopeptidasesRNA, Long NoncodingBiomarkersCase-Control StudiesHumansROC CurveAmyloid Precursor Protein SecretasesAspartic Acid EndopeptidasesBACE1 protein, humanBiomarkersRNA, Long NoncodingAlzheimer diseaseBiomarkerDiagnosisLong non-coding RNA

Identifiers

PMID29316899
PMCPMC5761117
OpenAlexW2783732909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.